pemafibrate
Kowa Pharmaceuticals
['cardio']
in the prominent trial, pemafibrate lowered triglycerides but did not cut the incidence of cv events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia #aha22 #cardiotwitter 
The content you need, when you need it.